Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03639025 · ClinicalTrials.gov registry record
OCS™ Lung TOP Registry For Donor Lungs for Transplantation
A clinical trial of Lung Transplantation, sponsored by TransMedics.
- Active
- Registry status
- 458
- Enrollment target
- 18
- Study locations
NCT03639025: Active study of Lung Transplantation, sponsored by TransMedics.
NCT03639025 is a study of Lung Transplantation that is active but no longer recruiting, run by TransMedics. The registered enrollment target is 458 participants, above the 298-participant average among 12 other Lung Transplantation trials with a reported enrollment target (54% higher). The trial reports 18 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03639025, a study of Lung Transplantation, is active but no longer recruiting, sponsored by TransMedics.
- ACTIVE NOT RECRUITING
- Registry status
- 458 participants
- Enrollment target
- 18
- Study locations
Study Summary
Single-arm, prospective, multi-center, post-approval U.S. registry
Primary Outcome
Primary Effectiveness Endpoint
Conditions Studied
Interventions
- DEVICE OCS Lung System
Study Locations (18)
California
- UCLA - Los Angeles
- Stanford University - Palo Alto
- UCSF - San Francisco
Texas
- Baylor Scott & White Research Institute - Dallas
- Baylor St. Luke's Medical Center - Houston
- Houston Methodist - Houston
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
Florida
- Tampa General Hospital - Tampa
Georgia
- Emory - Atlanta
Illinois
- University of Chicago - Chicago
Maryland
- Johns Hopkins - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 458 participants |
| Start Date | 2018-12-10 |
| Est. Completion | 2029-11-30 |
What the registry record for NCT03639025 still lists
NCT03639025 is an observational study that tracks outcomes without assigning an intervention. The registered 458 participants enrollment target is mid-sized for trials with a published cap, above the 298-participant average among 12 other Lung Transplantation trials with a reported enrollment target (54% higher).
The record links to 1 condition, with Lung Transplantation appearing as the primary indexed condition, and to 1 intervention - of which OCS Lung System is the first listed.
NCT03639025 lists 18 locations in 14 states (California, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT03639025 about?
NCT03639025 is a clinical study titled "OCS™ Lung TOP Registry For Donor Lungs for Transplantation". Single-arm, prospective, multi-center, post-approval U.S. registry
What is the current status of trial NCT03639025?
This trial is currently active not recruiting. The enrollment target is 458 participants. The study started on 2018-12-10. Estimated completion is 2029-11-30.
What conditions does trial NCT03639025 study?
This clinical trial studies the following conditions: Lung Transplantation.
What interventions are being tested in trial NCT03639025?
The interventions under investigation include: OCS Lung System (DEVICE).
Who is sponsoring clinical trial NCT03639025?
This trial is sponsored by TransMedics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03639025 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03639025's enrollment target sits among peer trials
458 4th of 12 higher than 9 of 12 other Lung Transplantation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Transplantation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
RECRUITING
-
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
RECRUITING · Phase 2
-
Trifecta-Lung cfDNA-MMDx Study
RECRUITING
-
Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
RECRUITING
-
Transplanting Lungs From Uncontrolled Donation After Circulatory Death
RECRUITING · NA
-
This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05856942 · 458 participants · NA
Hybrid Evaluation of a Home-based HIV Pre-exposure Prophylaxis Program
- NCT06201676 · 458 participants · Phase 4
Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients
- NCT04452825 · 459 participants · NA
A New Psychotherapy Intervention for Older Cancer Patients
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI